Biodesix (BDSX) Common Equity (2019 - 2026)

Biodesix has reported Common Equity for 8 years, with the latest figure at $9.1 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 17.43% year-over-year to $9.1 million; the trailing twelve-month figure through Mar 2026 stood at $9.1 million (down 17.43% YoY), and the FY2025 full-year result was -$2.5 million, down 111.81% from the prior year.
• Common Equity for Q1 2026 stood at $9.1 million, up from -$2.5 million in the prior quarter.
• The five-year high for Common Equity was $36.3 million in Q2 2024, with the low at -$7.0 million in Q2 2023.
• Historically, Common Equity has averaged $7.7 million across 5 years, with a median of $4.6 million in 2023.
• The largest YoY upside for Common Equity was 2026.49% in 2024 against a maximum downside of 220.92% in 2024.
• Biodesix's Common Equity stood at $20.6 million in 2022, then sank by 77.77% to $4.6 million in 2023, then soared by 355.81% to $20.9 million in 2024, then tumbled by 111.81% to -$2.5 million in 2025, then soared by 470.47% to $9.1 million in 2026.
• The last three Common Equity figures came in at $9.1 million (Q1 2026), -$2.5 million (Q4 2025), and -$1.7 million (Q3 2025), per Business Quant data.